H Yang
Shandong University
3 Papers
H Yang is an academic researcher from Shandong University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high risk, early breast cancer.
Charles E. Geyer,Judy Garber,R. D. Gelber,Greg Yothers,M Taboada,Louetta A. Ross,PS Rastogi,Karen Y. Cui,Amal Arahmani,Gursel Aktan,A. Armstrong,Monica Arnedos,Judith Balmaña,Joop P. W. van den Bergh,J. Bliss,S. Delaloge,S. Domchek,Andrea Eisen,F. Elsafy,Luis Fein,Anitra Fielding,James M. Ford,S. Friedman,Karen A. Gelmon,L. Gianni,Michael Gnant,Simon J. Hollingsworth,Sa Im,Agnes Jager,Oskar T. Johannsson,Sunil R. Lakhani,Wolfgang Janni,Barbro Linderholm,T-W. Liu,Niklas Loman,Larissa A. Korde,S. Loibl,P. Lucas,Frederik Marmé,Eduardo Martínez de Dueñas,Robin McConnell,Kelly-Anne Phillips,Martine Piccart,Giovanna Rossi,R. K. Schmutzler,Elżbieta Senkus,Z Shao,Paramananda Dash Sharma,C. Singer,Tanja Spanic,Elmar Stickeler,Masakazu Toi,TA Traina,Giuseppe Viale,Gabriele Zoppoli,Y. Park,Rinat Yerushalmi,H Yang,Dan-mei Pang,KH Jung,A. Mailliez,Zusen Fan,Isabelle Tennevet,G. Q. Zhang,Tauana Nagy,GS Sonke,Q. Sun,Marina Parton,Marco Colleoni,M. Schmidt,Adam Brufsky,Wajeeha Razaq,Bela Kaufman,D. Cameron,Carolyn Campbell,A. Tutt +75 more
TL;DR: The randomized OlympiA trial as discussed by the authors compared 1 year of the oral poly(adenosine diphosphate-ribose) polymerase inhibitor, olaparib, to matching placebo as adjuvant therapy for patients with pathogenic or likely pathogenic variants in BRCA1/2pv and high-risk, human epidermal growth factor receptor 2-negative, early breast cancer.
261
758P A comprehensive analysis of tumor-infiltrating immune cells in HPV-associated cancers
TL;DR: In 2018, 690,000 (31%) of the 2.2 million new infection-attributable cases of cancer diagnosed in 2018, human papillomavirus (HPV) is the second most important infectious cause of cancer worldwide as mentioned in this paper .
Histone deacetylase inhibitor SAHA epigenetically regulates miR-17-92 cluster and MCM7 to upregulate MICA expression in hepatoma
TL;DR: The HDACi SAHA epigenetically upregulates MICA expression through regulating the expression of miR-17-92 cluster and MCM7 in hepatoma, thus enhancing the sensitivity of HCC to natural killer cell-mediated lysis.